Sample size determination for cost-effectiveness trials

PharmacoEconomics

Volumn 29, Issue 11, 2011, Pages 933-949

  Willan, Andrew R ^a  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

Bayesian analysis; Clinical trial design; Cost effectiveness; Randomised controlled trials; Statistics.

Indexed keywords

CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; PLACEBO;

ARTICLE; BAYES THEOREM; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DECISION THEORY; FREQUENTIST APPROACH; HUMAN; INCREMENTAL NET BENEFIT; METHODOLOGY; PRIORITY JOURNAL; PROBABILITY; SAMPLE SIZE; STATISTICAL ANALYSIS;

EID: 80054115401     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11587130-000000000-00000     Document Type: Article

References (68)

1. O'Brien BJ, Drummond MF, Labelle RJ, et al. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in heath care. Med Care 1994; 32: 150-63
2. Mullahy J, Manning W. Statistical issues of cost-effectiveness analysis. In: Sloan F, editor. Valuing health care. Cambridge: Cambridge University Press, 1994
3. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E ratios alongside a clinical trial. Health Econ 1994; 3: 309-19
4. Wakker P, Klaassen MP. Confidence intervals for cost/ effectiveness ratios. Health Econ 1995; 4 (5): 373-81
5. Willan AR, O'Brien BJ. Confidence intervals for costeffectiveness ratios: an application of Fieller's theorem. Health Econ 1996; 5: 297-305 (Pubitemid 126483212)
6. Chaudhary MA, Stearns SC. Confidence intervals for costeffectiveness ratios: an example from a randomized trial. Stat Med 1996; 15: 1447-58 (Pubitemid 26242553)
7. Mullahy J. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation. Med Care 1996; 34 (12 Suppl.): DS124-35
8. Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost effectiveness in health and medicine. New York: Oxford University Press, 1996
9. Briggs AH, Wonderling DE, Mooney CZ. Pulling costeffectiveness analysis up by its bootstraps: a nonparametric approach to confidence interval estimation. Health Econ 1997; 6: 327-40 (Pubitemid 27384638)
10. Polsky D, Glick HA, Willke R, et al. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 1997; 6: 243-52 (Pubitemid 27296588)
11. Severens JL, De Boo TM, Konst EM. Uncertainty of incremental cost-effectiveness ratios. Int J Technol Assess Health Care 1999; 15: 608-14
12. Briggs AH, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane.Health Econ 1998; 7: 723-40 (Pubitemid 29012095)
13. Briggs AH, Gray AM. Power and sample size calculations for cost-effectiveness studies. Med Decis Making 1998; 18 (2 Suppl.): S81-92 (Pubitemid 28175945)
14. Laska EM, Meisner M, Siegel C. Power and sample in costeffectiveness analysis. Med Decis Making 1999; 19: 339-43
15. Briggs AH, Mooney CZ, Wonderling DE. Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation. Stat Med 1999; 18: 3245-62
16. Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. BMJ 1999; 319: 635-8 (Pubitemid 29414568)
17. Heitjan DF, Moskowitz AJ,WhangW. Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Econ 1999; 8: 191-201 (Pubitemid 29219084)
18. Briggs AH. A Bayesian approach to stochastic costeffectiveness analysis. Health Econ 1999; 8: 257-61 (Pubitemid 29219090)
19. Willan AR, O'Brien BJ. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Econ 1999; 8: 203-11 (Pubitemid 29219085)
20. Gardiner JC, Huebner M, Jetton J, et al. Power and sample size assessments for test of hypotheses on cost-effectiveness ratios. Health Econ 2000; 9: 227-34 (Pubitemid 30248639)
21. Phelps CE, Mushlin AI. On the (near) equivalence of osteffectiveness and cost-benefit analysis. Int J Technol Assess Health Care 1991; 7: 12-21
22. Ament A, Baltussen R. The interpretation of results of economic evaluation: explicating the value of health. Health Econ 1997; 6: 625-35 (Pubitemid 28021627)
23. Stinnett AA, Mallahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18 (2 Suppl.): S68-80 (Pubitemid 28175944)
24. Tambour M, Zethraeus N, Johannesson M. A note on confidence intervals in cost-effectiveness analysis. Int J Technol Assess Health Care 1998; 14: 467-71 (Pubitemid 28433890)
25. Heithan DF. Fieller's method and net health benefit. Health Econ 2000; 9: 327-35
26. Willan AR. Analysis, sample size and power for estimating incremental net benefit from clinical trials data. Control Clin Trials 2001; 22 (3): 228-37 (Pubitemid 32522469)
27. Willan AR, Lin DY. Incremental net benefit in randomized clinical trials. Stat Med 2001; 20: 1563-74 (Pubitemid 32577128)
28. Willan AR, Chen EB, Cook RJ, et al. Incremental net benefit in randomized clinical trials with quality-adjusted survival. Stat Med 2003; 22: 353-62 (Pubitemid 36163591)
29. Willan AR, Briggs AH. The statistical analysis of costeffectiveness data. Chichester: Wiley, 2006
30. Beaton DE, Bombardier C, Katz JN, et al. Looking for important change/differences in studies of responsiveness. J Rheumatol 2001; 28: 400-5 (Pubitemid 32165160)
31. Redelmeier DA, Guyatt GH, Goldstein RS. On the debate over methods for estimating the clinically important difference. J Clin Epidemiol 1996; 49: 1223-4 (Pubitemid 26386227)
32. Copay AG, Subach BR, Glassman SD, et al. Understanding the minimum clinically important difference: a review of concepts and methods. Spine 2007; 7: 541-6 (Pubitemid 47471437)
33. Lemeshow S, Hosmer Jr DW, Klar J, et al. The adequacy of sample size in health studies. New York: John Wiley and Sons, 1990
34. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 1981; 2: 93-113 (Pubitemid 11006595)
35. O'Hagan A, Stevens JW. Bayesian assessment of sample size for clinical trials of cost-effectiveness. Med Decis Making 2001; 21 (3): 219-30 (Pubitemid 32452766)
36. Willan AR, Cruess AF, Ballantyne M. Argon green vs krypton red laser photocoagulation of extrafoveal choroidal neovascular lesions: three-year results in age-related macular generation. Can J Ophthalmol 1996; 31: 11-7 (Pubitemid 26101420)
37. Hannah ME, Hannah WJ, Hewson SH, et al. Term breech trial: a multicentre international randomised controlled trial of planned caesarean section and planned vaginal birth for breech presentation at term. Lancet 2000; 356: 1375-83
38. Willan AR. Power function arguments in support of an alternative approach for analyzing management trials. Control Clin Trials 1994; 15: 211-9 (Pubitemid 24163703)
39. Berry DA, Ho C-H. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach. Biometrics 1998; 44: 219-27
40. Gittins J, Pezeshk H. How large should a trial be? Statistician 2000; 49: 177-97
41. Gittins J, Pezeshk H. A behavioral Bayes method for determining the size of a clinical trial. Drug Inf J 2002; 34: 355-63
42. Gittins J, Pezeshk H. A decision theoretic approach to sample size determination in clinical trials. J Biopharm Stat 2002; 12: 535-51 (Pubitemid 35439798)
43. ChengY, Su F, Berry DA. Choosing sample size for a clinical trial using decision analysis. Biometrika 2003; 90: 923-36 (Pubitemid 39047129)
44. Pezeshk H. Bayesian techniques for sample size determination in clinical trials: a short review. Stat Methods Med Res 2003; 12: 489-504 (Pubitemid 37461098)
45. Pezeshk H, Gittins J. Bayesian approaches to determine the number of subsequent users of a new treatment. Stat Methods Med Res 2006; 15: 585-92 (Pubitemid 46099249)
46. Hornberger JC, Brown Jr BW, Halpern J. Designing a costeffective clinical trial. Stat Med 1995; 14: 2249-59
47. Claxton K, Posnett J. An economic approach to clinical trial design and research priority setting. Health Econ 1996; 5: 513-24
48. Hornberger J, Eghtesady P. The cost-benefit of a randomized trial to a health care organization. Control Clin Trials 1998; 19: 198-211 (Pubitemid 28191974)
49. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18: 341-64 (Pubitemid 29242816)
50. Halpern J, Brown Jr BW, Hornberger J. The sample size for a clinical trial: a Bayesian-decision theoretic approach. Stat Med 2001; 20: 841-58 (Pubitemid 32249084)
51. Claxton K, Thompson KM. A dynamic programming approach to the efficient design of clinical trials. J Health Econ 2001; 20: 797-822 (Pubitemid 32743392)
52. Willan AR, Pinto EM. The expected value of information and optimal clinical trial design [published erratum appears in Stat Med 2006; 25 (4): 720]. Stat Med 2005; 24: 1791-806
53. Willan AR. Clinical decision making and the expected value of information. Clin Trials 2007; 4: 279-85 (Pubitemid 47400539)
54. Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ 2007; 16: 195-209 (Pubitemid 46206613)
55. Eckermann S, Willan AR. Time and EVSI wait for no patient. Value Health 2008; 11: 522-6
56. Eckermann S, Willan AR. The option value of delay in health technology assessment. MedDecis Making 2008; 28: 300-5 (Pubitemid 351713293)
57. Kikuchi T, Pezeshk H, Gittins J. A Bayesian cost-benefit approach to the determination of sample size in clinical trials. Stat Med 2008; 27: 68-82 (Pubitemid 351193660)
58. Willan AR. Optimal sample size determinations from an industry perspective based on the expected value of information. Clin Trials 2008; 5 (6): 587-94
59. Willan AR, Kowgier ME. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. Clin Trials 2008; 5: 289-300
60. Eckermann S, Willan AR. Globally optimal trial design for local decision making. Health Econ 2009; 18: 203-16
61. Willan AR, Eckermann S. Optimal clinical trial design using value of information methods with imperfect implementation. Health Econ 2010; 19: 549-61
62. Willan AR, Eckermann S. Accounting for between-study variation in value of information methodology. Health Econ. Epub 2011 Sep 1. DOI 10.1002/hec.1781
63. Grundy PM, Healy MJR, Rees DH. Economic choice of the amount of experimentation. J R Stat Soc Series B Stat Methodol 1956; 18: 32-48
64. Raiffa H, Schlaifer R. Applied statistical decision theory. Cambridge (MA): Harvard University, Graduate School of Business Administration, 1961
65. Nixon RM, Thompson SG. Parametric modelling of cost data in medical studies. Stat Med 2004; 23 (8): 1311-31 (Pubitemid 38514826)
66. Briggs A, Nixon R, Dixon S, et al. Parametric modelling of cost data: some simulation evidence. Health Econ 2005; 14 (4): 421-8 (Pubitemid 40514754)
67. Chiba N, van Zanten SJ, Sinclair P, et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the CanadianAdult Dyspepsia Empiric Treatment-Helicobacter pylori positive (CADET-Hp) randomized controlled trial. BMJ 2002; 324 (7344): 1012-6 (Pubitemid 34457514)
68. Willan AR. Incremental net benefit in the analysis of economic data from clinical trials with application to the CADET-Hp Trial. Eur J Gastroenterol Hepatol 2004; 16 (6): 543-9. (Pubitemid 38703862)